斑块状银屑病中TYK2与JAK-STAT信号通路及抑制作用
本文综述JAK-STAT及TYK2信号通路在斑块状银屑病中的作用,并总结JAK抑制剂疗效与安全性。TYK2变构抑制剂可能降低泛JAK抑制剂的毒性风险,deucravacitinib及brepocitinib等TYK2抑制剂正在研发中。
要点
- TYK2调控IL-12、IL-23及I型干扰素受体下游信号。
- 选择性TYK2变构抑制可能减少泛JAK抑制剂相关毒性。
- 多种TYK2抑制剂正开发用于银屑病治疗。
核心结论
- 选择性TYK2变构抑制可能降低泛JAK抑制剂相关毒性风险。
研究设计与样本
- 本文为综述,回顾JAK-STAT与TYK2信号通路及JAK抑制剂在银屑病中的疗效与安全性。
主要发现
- JAK1-3抑制剂在中重度银屑病患者中显示疗效,但安全性顾虑持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis. Although Janus kinase (JAK) 1-3 inhibitors have demonstrated efficacy in patients with moderate-to-severe psoriasis, safety concerns persist and no JAK inhibitor has received regulatory approval to treat psoriasis. Thus, an opportunity exists for novel oral therapies that are safe and efficacious in psoriasis. Tyrosine kinase 2 (TYK2) is a member of the JAK family of kinases and regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors. Deucravacitinib, which is an oral, selective inhibitor that binds to the regulatory domain of TYK2, and brepocitinib (PF-06700841) and PF-06826647, which are topical and oral TYK2 inhibitors, respectively, that bind to the active (adenosine triphosphate-binding) site in the catalytic domain, are in development for psoriasis. Selective, allosteric inhibition of TYK2 signaling may reduce the potential for toxicities associated with pan-JAK inhibitors. This article reviews Janus kinase-signal transducer and activator of transcription and TYK2 signaling and the efficacy and safety of JAK inhibitors in psoriasis to date, focusing specifically on TYK2 inhibitors.
引用
- Krueger JG, McInnes IB, Blauvelt A, et al. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2021. PMID: 34224773. doi:10.1016/j.jaad.2021.06.869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。